NCT06666179View on ClinicalTrials.gov

Safety and Immunogenicity Study of SCB-1019T in Children

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
RSV Infection
Interventions
BIOLOGICAL

low dose SCB-1019T

Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)

BIOLOGICAL

adjuvanted low dose SCB-1019T

Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)

BIOLOGICAL

high dose SCB-1019T

Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)

BIOLOGICAL

adjuvanted high dose SCB-1019T

Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)

OTHER

Placebo

0.9% NaCl saline placebo

Trial Locations (1)

6009

The Kids Research Institute, Perth

Sponsors
All Listed Sponsors
lead

Clover Biopharmaceuticals AUS Pty

INDUSTRY